Drugs / BI 3923948
last change Apr 2026 re-read 2 minutes ago

BI 3923948

Developed for
cancer
Investigated by
Boehringer Ingelheim

Trials 1 · a red edge is where a trial was stopped

20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07395258 Apr 2026 → Feb 2028 cancer Boehringer Ingelheim Suspended No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BI 3923948 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07395258
Route Other “BI 3923948 is given as injection(s) into the tumor” NCT07395258